As a global clinical research organization, we look forward to the DIA 2017 Annual Meeting every year because we have the opportunity to network, attend thought-provoking sessions, and collaborate with the innovative professionals in the pharmaceutical, biotechnology, and medical device communities.
This year, we’ll also be recognizing an important milestone as Medpace celebrates 25 years of accelerating the global development of safe and effective medical therapeutics. Since 1992, we have been providing full-service clinical research development services to Sponsors who develop therapeutics in our core therapeutic areas. If you are planning to attend the DIA meeting, we invite you to stop by booth 1118. We will have a team of medical, operational, feasibility, and patient recruitment experts who would welcome the opportunity to discuss your clinical research needs and challenges. You will have the opportunity to learn more about Medpace by playing an interactive game at the booth, designed to introduce you to Medpace capabilities and services. As a thank you for stopping by, you will stride home in your signature pair of Medpace socks.
Medpace Neurologist to Present during the Conference
One of Medpace’s most experienced neurologists will be presenting at DIA 2017. Richard Scheyer, MD, Vice President of Medical Affairs at Medpace, will be presenting during the following session “Serving the Patient Who Needs Early Access to Treatments and Achieving Meaningful Outcomes.” His presentation is titled “Aligning Objectives of Drug Development” and he will aim to guide drug developers in designing programs that address patient needs without compromising drug development. We encourage you to add this session to your DIA agenda. Here is a link to the session so you can view it in its entirety. Dr. Scheyer will also be available for meetings throughout the week. If you are interested in scheduling a meeting with him, please email us at info@emdevmedpace.wpengine.com.
About Richard Scheyer, MD
Dr. Scheyer is a pioneer in translational medicine and Phase I/IIa drug development, with special interest in early demonstration of clinical efficacy. Prior to joining Medpace, Dr. Scheyer held a number of leadership roles at biopharmaceutical firms where he was responsible for early clinical, biomarker, and pharmacogenomic strategy and execution.
Dr. Scheyer received his B.S. in Physics from Stanford University, his M.D. from The State University of New York, Upstate Medical University, and completed residency training in Neurology and fellowship training in Epilepsy and Clinical Pharmacology at Yale University before joining the Yale faculty, serving as Associate Professor of Neurology. He has served on the Foundation for the NIH Biomarkers Consortium, and on Board of Directors of the Serious Adverse Event Consortium. Dr. Scheyer is a highly-regarded author, speaker, and industry participant and has published over 60 manuscripts and abstracts, with a focus on clinical pharmacology and therapeutic activity in areas ranging from diabetes to oncology.